Marshall Wace’s Aldeyra Therapeutics ALDX Stock Holding History

Marshall Wace’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.21M	Buy	1,506,974 +1,377,281	+1,062%	+$2.37M	﹤0.01%	1594
2026 Q1	$219K	Buy	+129,693	New	+$568K	﹤0.01%	2757
2025 Q4	–	Sell	-160,213	Closed	-$836K	–	2921
2025 Q3	$836K	Buy	+160,213	New	+$835K	﹤0.01%	2018
2023 Q3	–	Sell	-183,337	Closed	-$1.54M	–	2151
2023 Q2	$1.54M	Buy	183,337 +106,232	+138%	+$1.05M	﹤0.01%	1527
2023 Q1	$766K	Sell	77,105 -245,476	-76%	-$1.74M	﹤0.01%	1928
2022 Q4	$2.25M	Buy	322,581 +122,418	+61%	+$700K	0.01%	1672
2022 Q3	$1.07M	Buy	200,163 +122,482	+158%	+$735K	﹤0.01%	2371
2022 Q2	$309K	Buy	+77,681	New	+$267K	﹤0.01%	3014
2018 Q4	–	Sell	-15,835	Closed	-$219K	–	1567
2018 Q3	$219K	Buy	+15,835	New	+$128K	﹤0.01%	1057

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Marshall Wace's ALDX Position: Q2 2026 in Review

Marshall Wace increased its Aldeyra Therapeutics (ALDX) stake by 1,062% in Q2 2026, buying an estimated $2.37M and bringing the position to 1,506,974 shares worth $3.21M. The position accounts for ﹤0.01% of the portfolio, ranked #1594.

Marshall Wace first reported a position in ALDX in Q3 2018 and has held it in 9 quarters since. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

Marshall Wace held 1,506,974 shares of Aldeyra Therapeutics worth $3.21M as of Q2 2026.
Marshall Wace bought 1,377,281 Aldeyra Therapeutics shares in Q2 2026, an estimated $2.37M.
Aldeyra Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1594 holding.
Marshall Wace first reported a position in Aldeyra Therapeutics in Q3 2018 and has held it in 9 quarters since.
108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.